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1 Drug description 
Generic/Brand name:  
Azacitidine/ Vidaza® 
Developer/Company:  
Celgene Corporation 
Description:  
Azacitidine (Vidaza ®), a new molecular entity, is a pyrimidine analogue 
with antineoplastic activity. Mechanisms of action include cytotoxicity on 
abnormal hematopoietic cells in the bone marrow and hypomethylation of 
DNA. Aberrantly methylated genes which are responsible for regulation of 
cell differentiation, death-pathways and cell-cycles, are believed to be re-
expressed due to hypomethylation, leading to an uptake of cancer 
suppressing actitivities. Cytotoxic effects are exerted by incorporation and 
inhibition of DNA and RNA, resulting in an activation of DNA damage 
pathways [1]..  
The recommended treatment regimen consists of the subcutaneous injection 
of 75mg/m² body surface area every day for 7 days, followed by three weeks 
without treatment (28-day treatment cycle). In case of local problems at the 
injection site, intravenous treatment is also easily feasible. A full course of 
treatment should consist of a minimum of six cycles and should be 
continued as long as the patient continues to benefit or until disease 
progression is stopped [1]. 
Prior to every treatment cycle, laboratory blood tests (complete blood 
counts, liver function, serum creatinine) should be performed [1]. 
2 Indication 
Azacitidine (Vidaza®) is indicated for the treatment of intermediate-2 and 
high risk MDS (according to International Prognostic Scoring System 
(IPSS)), chronic myelomonocytic leukemia and acute myeloid leukaemia in 
adults who are not eligible for haematopoietic stem-cell transplantation.   
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3 Burden of disease 
Myelodysplastic syndromes (MDS) are caused by dysfunctions of the bone 
marrow and might develop de-novo or as a secondary MDS after chemother-
apy or radiation therapy for other diseases [2]. The inability of the bone 
marrow to produce mature blood cells results in cytopenia of one or more of 
the peripheral blood cells and in an increasing number of bone marrow blast 
cells – factors which relate directly to the prognosis [3]. Symptoms include 
anaemia, repeated infections or bleeding.  About one third of patients suffer-
ing from MDS progress to acute myeloid leukaemia (AML)  [3]. 
By reasons that MDS comprise a heterogeneous group of conditions differ-
ent classification schemes, mainly based on the cellular morphology, are in 
use, such as the French-American-British Classification (FAB) or the World 
Health Organization’s (WHO) classification [2]. To assess the individual 
risk, the IPSS discriminates four risk groups. Based on number of cytopenia, 
percentage of marrow blasts and karyotype different prognoses for survival 
and transformation to AML can be made for each risk-group [3]. 
No data is available on the overall incidence of MDS in Austria but esti-
mates from other countries range from 3.3 [4] to 5 per 100,000 people per 
year [5]. Applied to an Austrian population of 8,355,000 [6], an estimated 
275 to 420 persons per year would be affected. Due to a constantly increasing 
elderly population stratum this number is likely to increase in the near fu-
ture.  
According to the IPSS, individual prognosis depends on the risk-group with 
a median survival (without therapy) ranging from 0.4 years to 5.7 years [7]. 
The research group which had developed the IPSS based their findings on 
816 patients. Within this study population they found that 22% of MDS pa-
tients had an intermediate-2 risk and 7% had a high risk MDS.  
The median age of diagnosis is about 70 to 75 years [4] with 90% of patients 
aged over 60 years at the time of diagnosis.  In individuals over 70 years the 
incidence rises to between 22 and 45 per 100,000 population per year [3].  
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4 Current treatment 
Treatment options for intermediate-2 and high-risk MDS patients comprise 
 Supportive care: transfusion of red blood cells or platelets; antibi-
otic therapy and prophylaxis to treat infections, and iron chelation. 
 Low dose chemotherapy (ARA-C, hydroxyurea, low dose melpha-
lan). 
 Allogeneic hematopoietic stem cell transplantation (HSCT) is the 
single available curative treatment option and should be offered as 
first-line therapy to eligible patients [8, 9]. Due to an  increasing 
risk of treatment-related mortality with increasing age, mainly 
younger patients are eligible [2]. However, modern concepts such as 
the use of dose reduced conditioning “mini-allo tranplantation” 
have moved generally accepted age limits for allogeneic transplan-
tation up to 70 years in selected patients.   
 High-intensity chemotherapy for eligible patients lacking a stem 
cell donor or to reduce marrow blast counts.   
 The use of haematopoietic growth factors (erythropoietin (off-
label), granulocyte-colony stimulation factor). 
 Decitabine, only as off-label use,  either for patients who are not eli-
gible for intensive therapy or as bridge to transplant if no donor is 
available [3]. 
5 Current regulatory status 
The European Medicines Agency (EMEA) granted market authorization for 
azacitidine in December 2008. Indications comprise the treatment of adults, 
if they are not eligible for bone marrow transplant and with: 
 intermediate-2 and high risk MDS according to the IPSS, 
 chronic myelomonocytic leukaemia (CMML) with 10% to 29%  
marrow blasts without myeloproliferative disorders, 
 AML with 20%  to 30% blasts (formerly known as refractory anae-
mia with excess blasts in transformation) and multi lineage dyspla-
sia, according to the WHO  classification [1].  
For MDS orphan medicinal product designation was granted in February 
2002 and for AML in November 2007.  
The United States Food and Drug Administration (FDA) has granted mar-
ket authorization for all MDS FAB subtypes in 2004 [10].  
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6 Evidence 
The evidence identified for this report comprises one phase III study, one 
phase II study and one retrospective analysis based on three trials. Addi-
tionally, one previous horizon scanning report on azacitidine was identified 
[11]. 
The phase III trial showed improved overall survival of patients with higher-
risk MDS treated with azacitidine in comparison to the three other treat-
ment regimens. Similarly, time to AML progression and haematological re-
sponse were more favourable for the azacitidine group. The phase II trial 
compared different dosing regimens of azacitidine in patients with lower-
risk MDS. All three treatment arms showed haematological improvements 
and increased transfusion independence. The retrospective reanalysis found 
increased median survival time for AML patients; response rates were ob-
served in between 40% and 47% of all patients treated with azacitidine.  
The most common side-effects were, according to the National Cancer Insti-
tute’s Common Toxicity Criteria, grade 3 or 4 haematological reactions (in 
up to 91% of patients). Rare but severe side-effects leading to death were 
sepsis and bleeding.  
6.1 Efficacy and safety - Phase III studie
Reference  NCT00071799,  Published [12] 
Sponsor Celgene Corporation 
Country Europe 
Design Randomized, open label, active control 
Participants characteristics 358 pts1 (I 179 vs C 179), median age: 69 years (range: 38 – 88 years) 
Treatments I(ntervention): azacitidine subcutaneous at 75mg/m2 per day for 7 days 
every 28 days for at least 6 cycles; 
treatment was continued until study completion (12 months after last 
patient was assigned) or discontinuation due to unacceptable toxicity, 
relapse, or disease progression 
 
C(onventional care as control group): 
- best supportive care 
- low-dose cytarabine 
- intensive chemotherapy (induction with cytarabine + daunorubi-
cin/idarubicin or mitoxantrone) 
In-/exclusion criteria Pts with higher-risk MDS - RAEB, RAEB-t or CMML (FAB Classification)2
Exclusion of pts with therapy-related MDS, previous azacitidine treat-
ment or planned allogeneic stem-cell transplantation 
Follow-up Until death or study completion 
 
1 pts =  patients 
2 RAEB = Refractory Anaemia with Excess Blasts, RAEB-t = Refractory Anaemia with Excess Blasts in Transforma-
tion; CMML = Chronic Myelomonocytic Leukaemia 
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Outcomes Primary: overall survival 
Secondary: time to transformation to AML, haematological response, in-
dependence from red-blood-cell transfusions, infections requiring antim-
icrobials, occurrence of adverse effects 
Key results  
(in comparison to conven-
tional care group) 
Overall survival 
at median follow-up of 21.1 months: I 24.5 months vs C 15 months 
(p=0.0001); HR3=0.58 (95% CI4 0.43 – 0.77); 
at 2 years: I 50.8% vs 26.2% (p< 0.0001) 
Median time to AML transformation: 
I 17.8 months vs C 11.5 months; HR= 0.5 (95% CI 0.35 – 0.70; p< 0.0001)
Haematological response:  
Any remission: I 29% vs C 12% (p=0.0001) 
Complete remission: I 17% vs C 8% (p=0.015) 
Partial remission: I 12% vs C 4% (p=0.0094) 
Rate of infections treated with antimicrobials (per patient/year): 
I 0.6 vs C 0.92; RR5= 0.66 (95% CI 0.49 – 0.87; p=0.0032) 
Adverse effects Deaths overall: I 46% vs C 63%, deaths during first 3 months I 11% vs C 
9% 
Neutropenia: I 91% vs C 76%, Thrombocytopenia: I 85%  vs C 80%, 
Anaemia: I 57% vs C 68% 
Other, non-haematological adverse effects: site reactions, nausea, vomit-
ing, fatigue, diarrhoea with azacitidine 
Commentary No significant difference between azacitidine and intensive chemother-
apy group in all outcome measures, except lower rates of infections for 
azacitidine, possible explanation: small number of patients 
 
3 HR = Hazard Ratio 
4 CI = Confidence Interval 
5 RR = Relative Risk 
 
This randomized controlled trial focused on patients with higher-risk MDS. 
By reason that three different treatment regimens acted as control, investiga-
tors determined, according to age, general condition and comorbidities, 
which conventional care treatment was most suitable for each individual pa-
tient before randomization. Patients were then randomly allocated one-to-
one to either azacitidine or conventional care regimens. Although overall 
baseline characteristics were well-balanced, some differences occurred 
within the three subgroups: as expected, patients in the high-intensity che-
motherapy group were younger, had better clinical performance status and 
higher-risk disease. Nevertheless, the majority of patients were allocated to 
the best supportive care group, suggesting that patients were representative 
of those where high-intensity treatments or stem-cell transplant were no 
treatment options.  
Overall survival of patients treated with azacitidine in comparison to the 
three most common therapy regimens was extended by 9.5 months. No dif-
ferences were found in time to AML progression when comparing azaciti-
dine and low-dose cytarabine or intensive chemotherapy.  
Furthermore, a subgroup analysis of azacitidine in comparison to intensive 
chemotherapy showed lower rates of infections for the azacitidine group but 
failed otherwise to demonstrate improved outcomes. Based on the fact that 
complete remission was achieved more often in the high-intensity chemo-
therapy group (in 36% of pts) than in the azacitidine group (in 29% of pts), 
the authors conclude that high-intensity chemotherapy prior to stem-cell 
transplantation might result in a better and faster reduction of bone marrow 
blasts than azacitidine.  
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Deaths observed in 82 patients (46%) in the intervention group and in 113 
patients (63%) in the control groups were considerably high. Of those, how-
ever, only four deaths in the azacitidine group (due to sepsis and bleeding) 
and one in the control group are believed to have been treatment related. 
Very common haematologic side-effects, most often responsible for treat-
ment discontinuation, were neutropenia, thrombocytopenia and anaemia, 
but independence from red-blood-cell transfusion as well as rate of infec-
tions requiring antimicrobials showed favourable outcomes for azacitidine.   
6.2 Efficacy and safety - further studies 
A phase II multicenter, randomized trial evaluated the impact of three dif-
ferent dosing regimens in a total of 151 patients [13]. The study population 
consisted mainly of patients with FAB lower-risk or RAEB. Hematologic 
improvement was observed in 44% to 56% of patients and transfusion inde-
pendence was achieved in 50% to 64% patients. Within the six-cycle treat-
ment phase adverse effects were neutropenia (38%), anaemia (29%), throm-
bocytopenia (25%) and leukopenia (18%). Non-haematological side-effects 
encompassed fatigue, nausea, erythema at the injection site and constipa-
tion. Out of three patients who died during treatment, one death is believed 
to have been treatment-related.  
Another publication reanalysed data of three trials, one randomized con-
trolled trial where patients were allowed to cross-over after 4 months and 
two trials with only one arm [14]. Of a total of 309 patients, 286 had been 
treated with azacitidine and out of those 48 had received the drug intrave-
nously. Across all azacitidine arms a treatment response (defined as com-
plete/partial remission or haematological improvements) was observed in 
40% to 47% of patients. A subgroup analysis of AML patients who had been 
participating in the randomized controlled trial showed a median survival 
time of 19.3 months in the intervention group compared to 12.9 months in 
the control group. Improvements in platelet and red blood cell transfusion 
were more often achieved in the active treatment arm. Adverse effects, in-
cluding haematologic and non-haematologic effects were seen more fre-
quently in the control group than in the intervention group. 
7 Estimated costs 
One vial of Vidaza® 100mg suspension for injection is approximately € 381 
(manufacturer’s price) [15]. Therefore, one course of treatment (6 cycles) is 
expected to be around € 32,000 (assuming an average body surface area of 
1.7m2 and therefore using 2 vials per day). These costs are alternatively to 
costs for other available treatment options for patients with intermediate-2 
to high-risk MDS, such as allogeneic hematopoietic stem cell transplanta-
tion or high-intensity chemotherapy [3]. 
One has to bear in mind that Vidaza® treatment in responders is usually 
given continuously until disease progression or dose limiting toxicity occurs, 
but will be adapted often to individual patients’ needs after the first cycles. 
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Therefore, a considerable proportion of patients will be on treatment for 
long periods of time.  
8 Ongoing research 
Three further phase III trials are currently enrolling patients:  
NCT00454480: will assess different chemotherapy regimens (including 
azacitidine) with combinations of monoclonal antibodies for the treatment 
of MDS and AML. First results can be expected in August 2012.  
NCT00887068: will evaluate the use of azacitidine after allogeneic trans-
plantation and is scheduled until April 2014.  
NCT00422890: azacitidine for the treatment of the haematological relapse in 
patients suffering from AML or MDS with falling CD34-chimerism after 
haematopoietic stem cell transplantation. Primary completion date is ex-
pected to be January 2010.  
Additionally, plenty of phase I and phase II trials are ongoing or recruiting 
patients. Research areas include azacitidine for patients with low-risk MDS, 
in combination with other treatment options for the management of 
MDS/AML or azacitidine prior to stem-cell transplantation in high-risk 
MDS [16] and fullblown AML. 
9 Commentary - English 
Based on the promising results of mainly one phase III study which demon-
strated increased survival rates for intermediate-2 to high-risk MDS patients 
in comparison to three other forms of treatment, European Union-wide mar-
ket authorization was granted by EMEA in December 2008 [1].  
So far, treatment options for higher-risk MDS patients included therapies 
such as  high-intensity chemotherapy and allogeneic HSCT [3].  However, 
eligibility for these treatment regimens depends on age, co-morbidities and 
clinical performance, hence only a limited number of patients are suitable. 
Thus, azacitidine provides a valuable treatment option for these difficult to 
treat MDS patients and has consequently found its way into daily clinical 
practice in Austria.  Nevertheless, data assessing azacitidine under real-life 
conditions are missing, emphasizing the need for pragmatic trials conducted 
by independent institutions and comparing azacitidine to, for example, con-
ventional chemotherapy regimens. 
Although decitabine, an azacitidine congener, can theoretically be used off-
label for the treatment of MDS patients, data from randomized phase III tri-
als reporting survival benefit for individuals treated with this drug are still 
missing [3].  
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Most commonly reported side-effects of azacitidine are haematologic reac-
tions occurring during the first two treatment cycles. Treatment options and 
preventive measures include monitoring of complete blood count, prophy-
lactic antibiotics, delay of azacitidine administration or red-blood-cell trans-
fusions [1].  
As subcutaneous administration provides an easy way of treatment delivery, 
self-administering at home is feasible [17]. Additionally, a phase I trial is re-
cruiting participants to assess the oral application of this drug which might 
facilitate its application even further [16].  
It is likely that azacitidine will be used more frequently in the near future: 
the FDA has approved the drug for all FAB-subtypes [10], the National 
Comprehensive Cancer Network has incorporated azacitidine into its clini-
cal practice guidelines for low-risk MDS patients as well as for patients who 
relapse after stem-cell transplant [3] and more studies to assess its value 
prior to/ after transplantation are under way. Therefore, off-label use in Aus-
tria is already going on.  
The economic consequences are unclear. On the one hand, by reasons that 
treatment should be continued as long as patients experience benefit or the 
disease does not progress [1] and combined with the potential of a more 
widespread use for broader indications (e.g. low risk MDS, stem-cell trans-
plant, AML in the elderly), costs might be considerable. On the other hand, 
increased transfusion independence and the self-administration at home 
could lead to a reduced use of in-patient services and therefore to cost sav-
ings. If the costs have to be borne mainly by hospital providers or will occur 
in the out-patient sector will depend on the presence of oncologists in own 
practices – a condition practically absent in Austria.  
10 Commentary - German 
Basierend auf den Ergebnissen einer Phase III Studie, die ein verlängertes   
Gesamtüberleben für MDS PatientInnen mit mittlerem Risiko 2 und hohem 
Risiko nach IPSS im Vergleich zu konventionellen Therapieformen gezeigt 
hatte, erhielt Azacitidine im Dezember 2008 von der EMEA die europaweite 
Marktzulassung [1].  
Therapien für Hochrisiko MDS PatientInnen, wie Stammzelltransplantati-
on oder intensive Chemotherapie, stellen nur für eine sehr limitierte Patien-
tInnengruppe eine Behandlungsoption dar, weil nur jüngere PatientInnen 
und Personen mit gutem Allgemeinzustand für diese Therapien geeignet 
sind [3]. Azacitidine bietet nun für diese vormals schwierig zu behandeln-
den PatientInnen eine wertvolle Therapiealternative dar und hat daher in 
Österreich bereits Eingang in den klinischen Alltag gefunden. Nichtsdesto-
trotz, Daten zur Wirksamkeit unter Realbedingungen sind noch ausständig, 
wobei vor allem pragmatische Studien von unabhängigen Institutionen, die 
Azacitidine mit herkömmlichen Chemotherapien vergleichen, wünschens-
wert wären.  
Obwohl zwar mit Decitabine generell ein ähnliches Produkt, wenn auch nur 
im „Off-label“ Gebrauch, zur Verfügung stehen würde, sind Daten aus ran-
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domisierten Phase III Studien, die ebenfalls ein verlängertes Gesamtüberle-
ben beweisen würden, für dieses Medikament noch ausständig.  
Die häufigsten beobachteten unerwünschten Nebenwirkungen von Azaciti-
dine waren hämatologische Reaktionen während der ersten beiden Behand-
lungszyklen. Vorsichtsmaßnahmen und Behandlungsoptionen für diese Ne-
benwirkungen beinhalten unter anderem regelmäßige Laborkontrollen, Ga-
be von Erythrozytenkonzentraten oder Antibiotika.  
Die subkutane Injektion von Azacitidine stellt eine unkomplizierte Art der 
Verabreichung dar und bietet PatientInnen auch die theoretische Möglich-
keit, sich den Wirkstoff selbst zu Hause zu verabreichen [17]. Die Einnahme 
dieses Medikaments könnte eine weitere Vereinfachung erfahren, weil die 
orale Gabe bereits Gegenstand weiterer klinischer Studien ist [16].  
Dass Azacitidine, zunächst für off-label und in weiterer Zukunft für ausge-
weitete Indikationsstellungen verwendet werden wird, ist sehr wahrschein-
lich, zumal die FDA Azacitidine für alle FAB- Subtypen zugelassen hat [10], 
das „National Comprehensive Cancer Network“ Azacitidine in seinen Gui-
delines auch für die Behandlung von Niedrigrisiko MDS Patientinnen in-
korporiert hat [3] und weitere Studien den Nachweis erbringen sollen, dass 
der Einsatz dieses Medikaments auch vor/nach Stammzelltransplantationen 
und im Rahmen der AML Therapie gerechtfertigt ist.  
Die Kostenkonsequenzen sind unklar. Auf der einen Seite könnten die an-
fallenden Ausgaben beträchtlich sein – vor allem bei Indikationsausweitun-
gen, der zunehmenden MDS Inzidenz und bedingt dadurch, dass die Thera-
pie fortgesetzt werden soll, solange PatientInnen davon profitieren und die 
Krankheit nicht fortschreitet [1]. Auf der anderen Seite könnte es durch den 
verminderten Transfusionsbedarf und durch die Möglichkeit der Selbstver-
abreichung zu einer verminderten Inanspruchnahme von stationä-
ren/ambulanten Aufenthalten kommen. Ob die Kosten letztlich hauptsäch-
lich von Krankenhausträgern zu bezahlen sein werden, wird von der Ver-
fügbarkeit niedergelassener Onkologen abhängen – eine Bedingung die in 
Österreich praktisch nirgends erfüllt ist.   
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